Marker Therapeutics Inc
NASDAQ:MRKR

Watchlist Manager
Marker Therapeutics Inc Logo
Marker Therapeutics Inc
NASDAQ:MRKR
Watchlist
Price: 2.12 USD 17.13% Market Closed
Market Cap: 35.3m USD

Operating Margin

-307%
Current
Declining
by 16.6%
vs 3-y average of -290.4%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-307%
=
Operating Income
$-14.4m
/
Revenue
$4.7m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
-307%
=
Operating Income
$-14.4m
/
Revenue
$4.7m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Marker Therapeutics Inc
NASDAQ:MRKR
35.4m USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
378.3B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
178.1B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
154.2B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
Loading...
AU
CSL Ltd
ASX:CSL
85.3B AUD
Loading...
NL
argenx SE
XBRU:ARGX
41.9B EUR
Loading...
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
46.9B USD
Loading...
No Stocks Found

Market Distribution

Lower than 90% of companies in the United States of America
Percentile
10th
Based on 14 112 companies
10th percentile
-307%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Marker Therapeutics Inc
Glance View

Market Cap
35.3m USD
Industry
Biotechnology

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company is headquartered in Houston, Texas and currently employs 56 full-time employees. The company went IPO on 2016-11-08. The firm specializes in the development and commercialization of T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The firm has developed its lead product candidates from its MultiTAA-specific T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor associated antigens (TAAs), which are tumor targets, and then kill tumor cells expressing those targets. The company has three MultiTAA-specific T cell therapies through clinical development, which include Autologous MultiTAA-specific T cell therapies, Allogeneic MultiTAA-specific T cell therapies and Off-the-shelf MultiTAA-specific T cell therapies. The firm is focused on developing MT-601 for the treatment of advanced unresectable pancreatic cancer.

MRKR Intrinsic Value
Not Available
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
-307%
=
Operating Income
$-14.4m
/
Revenue
$4.7m
What is Marker Therapeutics Inc's current Operating Margin?

The current Operating Margin for Marker Therapeutics Inc is -307%, which is below its 3-year median of -290.4%.

How has Operating Margin changed over time?

Over the last 3 years, Marker Therapeutics Inc’s Operating Margin has increased from -664.7% to -307%. During this period, it reached a low of -664.7% on Sep 30, 2022 and a high of -168.7% on Dec 31, 2024.

Back to Top